Our Mastery
Testimonial
- "Amazing success ratio in such uncertain market and paid service is very affordable ...Good job done by your team...keep it up guys."
-Venkat (Chennai)
Party Plot Owner - "I am trading in stock market since last 8 years; I have subscribed services from many advisory companies. Conclusion is that no one can provide 100% accuracy in this NSE market. But accuracy of intraday tips from this firm is the highest among all share tips companies" Rahul Varma (Mumbai)
Owner of an Insurance Firm - "I have taken free trial of intraday tips for 2 days and 80% call is profitable. Then I have subscribed paid membership for trading advice and now I am quite satisfied with services. Important thing is do not think more; Just trade what you are suggested" -Kevin Patel (Ahmedabad)
BDM at IT Company - "Made Good Profit in the Intraday, Jackpot Calls, F&o Tips. Overall Service is very good. Especially I like your Fast tips Sms Service & Exit Call System. Your tips have very good performance." -Manoj Arora (Delhi)
CEO of Real Estate Company
Cadila Healthcare Ltd share price today (on 22 September 2023).
We Provide Best stock tips for Cadila Healthcare Ltd. A1 Intraday Tips is accurate share tips Provider Company in India in Nse market. A1 Intraday Tips, also provide Daily Charts with Nse Share Market current price of Cadila Healthcare Ltd with today performance in nse market. Contact Us for Jackpot Stock tips.
Get Free Stock Tips for Cadila Healthcare Ltd
BSE: 532321 | NSE: CADILAHC | ISIN: INE010B01019 Market Cap: [Rs.Cr.] 18,260 | Face Value: [Rs.] 5 Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Cadila Healthcare Limited, an integrated healthcare company, discovers, develops, manufactures, and markets a range of healthcare products worldwide. The company offers active pharmaceutical ingredients, formulations, animal health products, and cosmeceuticals. It markets its products for various therapeutic applications, including cardiovascular, gastrointestinal, and women's healthcare, as well as for respiratory, pain management, central nervous system, anti-infectives, oncology, neurosciences,
Cadila Healthcare Ltd is a well known research-oriented, technology-driven pharmaceutical company focused on the research areas of biotechnology, formulations and Active Pharmaceutical Ingredients. They are an Indian based pharmaceutical company having their presence around the world. They are having their manufacturing facilities at Ahmedabad, Ankleshwar and Vadodara in Gujarat, Ponda in Goa, Raigad in Maharashtra and Solan in Himachal Pradesh. Cadila Healthcare Ltd, the flagship of Zydus Cadila Group was incorporated in May 1995 and they became a public limited company in July 1996. The company's operation includes pharmaceuticals, which includes human formulations, veterinary formulations and bulkdurgs, diagnostics, herbal products, skin care products and OTC products. In the year 1996, the company made a strategic alliance with Gulin Pharma of China and launched Falcigo in India, which is an anti-malarial segment.
In May 2000, the company acquired formulation business of Recon Ltd, which strengthens the company in the southern market. In the year 2001, they acquired German Remedies which was the largest M&A in the Indian Pharmaceutical sector and in the same year, they entered into a joint venture with US based Onconova for collaborative research in the field of Oncogenomics. In April 2002, the company acquired Banyan Chemicals, a Vadodara based company with the US FDA approved plant. In the year 2003, German Remedies, Recon Healthcare, Zoom Properties and Zydus Pathline merged with the company. Also, they acquired Alpharma France, which spearheaded the group operations in France. In the same year, the company emerged as a 'Partner of Choice' for Schering AG to manufacture and market the products in India. In November 2004, the company entered into a strategic alliance with Zambon Group in Italy to open up new avenues in contract manufacturing. In the same year, the company entered into a long term strategic pact with Boehringer Ingelheim India Ltd, a wholly owned subsidiary of Boerhringer Ingelheim (BI) to manufacture and market BI's products in India. In the year 2005, the company entered into a strategic alliance with Mallinckrodt Pharmaceuticals Generics, a business unit of Tyco Healthcare to market the product manufactured by the company under a joint label. In the same year, the company signed a 50:50 joint venture with Mayne Pharma of Australia to manufacture generic injectable, cytotoxic (anti-cancer) medicines as well as active pharmacetical ingredients (API) for global markets.
During the year 2005-06, the company signed a 50:50 joint venture with one of India's top biotech companies Bharat Serums and Vaccines Ltd (BSV) and formed Zydus BSV Pharma Pvt Ltd to develop, manufacture and market non-infringing and proprietary Novel Drug Delivery System (NDDS) of an approved anti-cancer product for global markets. During the year 2006-07, the company entered into share purchase agreement to acquire 97.95% stake in Liva Healthcare Ltd, which is carrying on business of manufacturing and marketing of Formulations. They established a green field facility for Solid Oral Dosage Forms in Sikkim mainly for domestic market. They also installed Lyophilisation facility at Moraiya plant with annual capacity of 7.5 million dosages to cater to both Indian and International markets. During the year 2007-08, the company restructured their formulation division namely Alidac and launched two new sub division namely Corza and Fortiza. Also, they forayed into the neutraceutical industry and launched a new division, Zydus Nutriva. The upgradation of the injectibles facility at Moraiya was completed and also, they expanded their manufacturing facility at Ankleshwar. Zydus Healthcare Brasil Ltd, Brazil, a wholly owned subsidiary of the company acquired 100% shareholding of Quimica e Farmaceutica Nikkho Do Brasil Ltda, a Brazilian Pharmaceutical company to expand their branded business in Brazil. Also, Zydus Pharmaceuticals Inc, Japan, a wholly owned subsidiary of the company acquired 100% shareholding in Nippon Universal Pharmaceuticals Co Ltd, Japanese Company, which is carrying out business of manufacturing and marketing of pharmaceutical products in Japan.
In February 2008, the company and Karo Bio of Sweden made a three year strategic collaboration in the area of drug discovery and development. The company is in the process of setting up a fine chemical facility at Dabhasa at a cost of about Rs. 200 million, which will commence their production in the financial year 2008-09. In May 2008, the company entered into Spain with the acquisition of 100% stake in Laboratories Combix. In June 2008, the company through their wholly owned subsidiary, Zydus Healthcare SA Pty Ltd is acquiring majority state of 70% in Simayla Pharmaceuticals of South Africa. The company decided to demerge the Consumer Products Division of the company and transferred to Carnation Nutra Analogue Foods Ltd, which is a subsidiary of Cadila Healthcare and the merger of Zydus Hospital and Medical Research Pvt Ltd with the company. In August 2008, the company has entered into an agreement with WHO to explore a possible collaboration in the development of a cocktail for the treatment of rabies, through the use of monoclonal antibodies.
According to the Consolidated - Audited financial statement for the Year of 2012, total net operating revenues increased with 14.50%, from INR 4,643.3 tens of millions to INR 5,316.4 tens of millions. Operating result increased from INR 580.5 tens of millions to INR 946.2 tens of millions which means 63.00% change. The results of the period decreased -6.26% reaching INR 681.2 tens of millions at the end of the period against INR 726.7 tens of millions last year. Return on equity (Net income/Total equity) went from 33.47% to 26.47%, the Return On Asset (Net income / Total Asset) went from 21.07% to 10.68% and the Net Profit Margin (Net Income/Net Sales) went from 15.65% to 12.81% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 247.87% compared to 158.80% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 1.83 to 1.88 when compared to the previous year.
( Equity cash, Nse fno, jackpot call, sure shot call, btst/stbt call )
Under one plan with lowest price
for free trial visit Stock tips for day Traders
Nse Listed Companies with Live Charts
with live charts starting with that Alphabet.)
| A | B | C | D | E | F | G | H | I | J |
| K | L | M | N | O | P | Q | R | S | T |
| U | V | W | X | Y | Z |
